


What is claimed is:

1. A compound comprising Formula I



5 wherein:

R¹, and R² are independently in each occurrence hydrogen, halogen, (C₁₋₆) - alkyl, -OR', -SR', -NR'R'', -SOR', -SO₂R', -COOR', -OCOR', -OCONR'R'', -OSO₂R', -OSO₂NR'R'', -NR'SO₂R'', -NR'COR'', -SO₂NR'R'', -SO₂(CH₂)₁₋₃CONR'R'', -CONR'R'', cyano, haloalkyl, or nitro; or

10 R' and R'' are independently in each occurrence hydrogen, (C₁₋₆)-alkyl, substituted lower alkyl, aryl, heterocyclyl, heteroaryl, aryl-(C₁₋₃)-alkyl, heteroaryl-(C₁₋₃)-alkyl, heterocyclyl-(C₁₋₃)-alkyl, cycloalkylalkyl, cycloalkyl, or R' and R'' together with the nitrogen they are attached may also form a 5- to 7- membered ring, optionally incorporating one additional ring heteroatom chosen from N, O or S(O)₀₋₂;

15 R³ is independently in each occurrence (C₁₋₆) alkyl, (C₁₋₆) alkenyl, (C₁₋₆) alkynyl, or cycloalkyl; or

one of X, Y or Z is independently S, O, or N-R⁴, the others are CH₂;

R⁴ is hydrogen, (C₁₋₆)-alkyl, haloalkyl, aryl(C₁₋₆)alkyl, heteroaryl(C₁₋₆)alkyl, -(C₁₋₆)-CR'R'R'', -COOR', -SO₂R', -C(O)R', -SO₂(CH₂)₀₋₃NR'R'', -CONR'R'', or -

20 PO(OR')₂, wherein R' and R'' are as defined above;

p is an integer from 1 to 3 inclusive;

m is an integer from 0 to 3 inclusive;

n is an integer from 1 to 6 inclusive;

or prodrugs, individual isomers, racemic or non-racemic mixtures of isomers, or

25 pharmaceutically acceptable salts or solvates thereof.

2. The compound of Claim 1, wherein p is 2.

3. The compound of Claim 1, wherein n is 3.

4. The compound of Claim 2, wherein n is 3.

5. The compound of Claim 2, wherein one of X, Y or Z is NR^4 , and the others are CH_2 .
6. The compound of Claim 5, wherein R^4 is hydrogen.
7. The compound of Claim 2, wherein m is 1.
- 5 8. The compound of Claim 2, wherein m is 2.
9. The compound of Claim 7, wherein Y is NR^4 , and X and Z are CH_2 .
10. The compound of Claim 9, wherein Y is NH, and X and Z are CH_2 .
11. The compound of Claim 8, wherein one of X, Y or Z is NR^4 , and the others are CH_2 .
- 10 12. The compound of Claim 11, wherein R^4 is H.
13. The compound of Claim 3, wherein one of X, Y or Z is NR^4 , and the others are CH_2 .
14. The compound of Claim 13, wherein p is 2.
15. The compound of Claim 14, wherein one of X, Y or Z is NH and the others are CH_2 .
- 15 16. The compound of Claim 14, wherein m is 2.
17. The compound of Claim 16, wherein X is NH, and Y and Z are CH_2 .
18. The compound of Claim 16, wherein Y is NH, and X and Z are CH_2 .
19. The compound of Claim 16, wherein Z is NH, and X and Y are CH_2 .
- 20 20. The compound of Claim 2, wherein m is 2, n is 3, and one of X, Y or Z is O and the others are CH_2 .
21. The compound of Claim 1 comprising 3,5-dimethyl-isoxazole-4-sulfonic acid 7-
{{4-(7-oxo-[1,4]diazepan-1-yl)-butyl}-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-
2-yl ester; 4-(2-dimethylamino-ethanesulfonyl)-1-{4-[(7-methoxy-1,2,3,4-
25 tetrahydro-naphthalen-2-yl)-propyl-amino]-butyl}-[1,4]diazepan-2-one; 4-{4-[(7-
methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-propyl-amino]-butyl}-[1,4]diazepan-
5-one; 4-{5-[(7-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-propyl-amino]-
pentyl}-[1,4]diazepan-5-one; 1-{4-[(7-methoxy-1,2,3,4-tetrahydro-naphthalen-2-
yl)-propyl-amino]-butyl}-[1,4]diazepan-2-one; 1-{4-[(7-bromo-1,2,3,4-tetrahydro-
30 naphthalen-2-yl)-propyl-amino]-butyl}-[1,4]diazepan-2-one; or 3-{4-[(6,7-


dimethoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-propyl-amino]-butyl}-

[1,3]oxazepan-2-one,

or a prodrug, an individual isomer, a racemic or non-racemic mixture of isomers, or pharmaceutically acceptable salt or solvate thereof.


- 5 22. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1 in admixture with a pharmaceutically acceptable carrier.
23. The pharmaceutical composition of Claim 22, wherein the compound is suitable for administration to a subject having a disease state which is alleviated by treatment with a M2/M3 muscarinic receptor antagonist.
- 10 24. A method of treatment comprising administering to a subject in need of such treatment, a therapeutically effective amount of at least one compound of Claim 1.
25. A method of treatment comprising administering to a subject in need of such treatment, a therapeutically effective amount of the composition of Claim 20.
- 15 26. The method of treatment of Claim 24, wherein the disease state is alleviated with a M2/M3 muscarinic antagonist.
27. The method of treatment of Claim 26, wherein the disease state is associated with smooth muscle disorders comprising diseases of the genitourinary or gastrointestinal tract, or of respiratory states.
- 20 28. The method of treatment of Claim 27, wherein the disease state is associated with the genitourinary tract.
29. The method of treatment of Claim 28, wherein the disease state comprises overactive bladder, detrusor hyperactivity, urgency, frequency, reduced bladder capacity, incontinence episodes, changes in bladder capacity, micturition
- 25 threshold, unstable bladder contractions, sphincteric spasticity, outlet obstruction, outlet insufficiency, pelvic hypersensitivity, idiopathic conditions or detrusor instability.
30. The method of treatment of Claim 27, wherein the disease state comprises respiratory states from allergies or asthma.
- 30 31. The method of treatment of Claim 27, wherein the disease state comprises gastrointestinal tract disorders.

32. A process for preparing a compound as claimed in Claim 1 which process comprises reacting a compound having a general formula




5

with a compound of general formula



to provide a compound of Formula I



10

wherein R¹, R², R³, p, m, n, X, Y, and Z are as defined in Claim 1.